Circulating microRNAs in cancer: origin, function and application by unknown
Ma et al. Journal of Experimental & Clinical Cancer Research 2012, 31:38
http://www.jeccr.com/content/31/1/38REVIEW Open AccessCirculating microRNAs in cancer: origin, function
and application
Ruimin Ma1, Tao Jiang2* and Xixiong Kang1*Abstract
MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the posttranscriptional
level. The dysregulation of miRNAs has been linked to a series of diseases, including various types of cancer. Since
their discovery in the circulation of cancer patients, there has been a steady increase in the study of circulating
miRNAs as stable, non-invasive biomarkers. However, the origin and function of circulating miRNAs has not been
systematically elucidated. In this review, we summarize the discovery of circulating miRNAs and their potential as
biomarkers. We further emphasize their possible origin and function. Finally, we discuss the application and existing
questions surrounding circulating miRNAs in cancer diagnostics. Although several challenges remain to be
concerned, circulating miRNAs could be useful, non-invasive biomarkers for cancer diagnosis.
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MicroRNAs (miRNAs) are approximately 22 nucleotides
long, endogenous, single-stranded, non-protein-coding
RNA molecules that regulate gene expression at the
posttranscriptional level. Since their discovery in 1993,
miRNAs have caused worldwide interest due to their
characteristic function and modes of action, providing a
new understanding of the central dogma of molecular
biology. MiRNAs have been shown to regulate a variety
of cellular processes, such as proliferation, differentiation,
metabolism, ageing and cell death. As such, the import-
ance of miRNAs is increasingly recognized in almost all
fields of biological and biomedical fields [1]. In humans, it
has been estimated that there are more than 1000 miRNAs
in the genome which regulate approximately 60% of all
protein-coding genes [2,3].
Recently, the importance of miRNAs in oncogenesis
has been recognized. Dysregulation of miRNA expression
plays a key role in cancer development through various
mechanisms including deletions, amplifications, epigenetic
silencing, or mutations in miRNA loci, the dysregulation
of transcription factors that target specific miRNAs [4].* Correspondence: clinical_lab@126.com; taojiang1964@yahoo.com.cn
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medium, provided the original work is properMiRNAs expression profiling studies, using microarrays
and other methods, can be used to differentiate normal
from cancer tissues as well as to classify different tumor
types and grades. Furthermore, specific miRNAs expres-
sion features have been found to correlate with cancer
prognosis and therefore have the potential to be used to
determine the course of treatment [5-7].
The discovery of circulating miRNAs in cancer
patients holds great promise for the use of miRNAs as
distinctive, non-invasive cancer biomarkers. In this review,
we focus on the origin and function of circulating miRNAs,
and discuss their characteristics and their potential applica-
tion as powerful biomarkers in cancer diagnostics. We also
discuss some issues that need to be further explored and
normalized before miRNAs can be successfully applied as
biomarkers in a clinical setting.Biomarkers in the circulation
Circulating biomarkers undoubtedly play an increas-
ingly significant role in clinical applications such as dis-
ease diagnostics, monitoring therapeutic effect and
predicting recurrence in cancer patients. The currently
used fluid-based biomarkers are primarily proteins,
such as alpha-fetoprotein (AFP) [8], chromogranin A
(CgA) [9], nuclear matrix protein 22 (NMP 22) [10],
carbohydrate antigen 125 (CA 125) [11]; enzymes, such
as prostate specific antigen (PSA) [12]; and humanThis is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
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markers provide an opportunity to analyze tumors com-
prehensively in an invasive way, low sensitivity and
specificity limit their clinical application. For example,
serum levels of AFP are often elevated in hepatocellular
carcinoma (HCC); however, this is also the case in germ
cell tumors, gastric, biliary and pancreatic cancers.
Moreover, serum levels of AFP are not consistently ele-
vated in HCC patients, but are commonly found at normal
or decreased levels [14]. Even for PSA, which is considered
a sensitive biomarker for advanced prostate cancer, serum
levels are often increased in men with benign prostatic
hyperplasia [15]. These points underscore the importance
of finding novel circulating biomarkers, such as miRNAs,
to supplement biomarkers currently used in tumor classifi-
cation and prognostication.
Chim et al. first identified the expression of miRNAs in
the circulation in 2008. They used quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) to
quantify miRNAs levels of apparent placental origin, in the
plasma of pregnant women [16]. Shortly thereafter, Lawrie
et al. reported elevated serum levels of miR-155, miR-210,
miR-21 in diffuse large B-cell lymphoma patients com-
pared with healthy controls. Moreover, high miR-21 ex-
pression was correlated to relapse-free survival [17].
These studies opened up the exciting prospect of utiliz-
ing circulating miRNAs as powerful, non-invasive diag-
nostic markers for cancers and other diseases.
Circulating miRNAs have many of the essential character-
istics of good biomarkers. First, they are stable in the circu-
lation and resistant to storage handling. Serum miRNAs are
resistant to RNase digestion and other harsh conditions
such as extreme pH, boiling, extended storage, and multiple
freeze-thaw cycles. Second, most miRNAs sequences are
conserved across species. Third, in some cases, changes in
miRNA levels in circulation have been associated with dif-
ferent diseases as well as certain biological or pathological
stages. Finally, miRNAs levels can easily be determined by
various methods [18-23].
Several major profiling platforms are used today in
miRNAs detection. A powerful method for the analysis
of serum miRNAs involves relative quantification by
stem-loop RT-PCR. This method has been widely used
for the sensitive detection of low abundance circulating
miRNAs [24]. Microarray analysis is also commonly used
in miRNAs detection but generally requires more starting
material than qRT-PCR, and can be complicated by the
need to develop probes and hybridization conditions that
can detect a variety of miRNAs concurrently [18]. Deep se-
quencing appears to be a very promising technique for
identifying novel miRNA biomarkers [25]. This technology
can be used to identify tissue and stage specific expression,
and compare data with miRNAs profiles in different dis-
eases [26-28]. These methods open exciting avenues fornon-invasive quantification of miRNAs. However, reprodu-
cibility among different methods remains a major concern.
Chen et al. found a weak correlation between results
obtained by qRT-PCR array and oligonucleotide microchip
methods, indicating considerable variability between the
two assay platforms [29]. Clearly, more work is necessary to
identify suitably standardized and normalized protocols.
Origin of circulating miRNAs
The question of whether tumor-associated miRNAs
detected in circulation results from tumor cell death
and lyses, or instead from secretion by tumor cells
remains unanswered. The latest findings concerning
exosomal miRNAs could uncover the miRNA secretory
mechanism.
As previously mentioned, miRNAs have proven to be
robust against external factors, such as enzymatic deg-
radation, freeze-thaw cycles, and extreme pH condi-
tions [30,31]. Mitchell et al., by applying multiple steps
of filtration and centrifugation to separate cells from
plasma and recover RNA from both sections, demon-
strated that serum miRNAs were not associated with
cells or larger cell fragments, but existed in a stable and
protected form [30]. The unexpected stability of circulating
miRNAs in blood begs the question of what mechanism
protects circulating miRNAs from degradation. Recent
studies have revealed that miRNAs may be protected either
in microvesicles (up to 1 μm) or in small membrane vesicles
of endocytic origin called exosomes (50–100 nm) [32,33].
Kosaka and colleagues found that miRNA are first incorpo-
rated into exosomal particles, after which a surge of cellular
ceramide stimulates the release of exosomes. Ceramide bio-
synthesis is regulated by neutral sphingomyelinase
(nSMase). Treated HEK293 cells with nSMase inhibitor,
GW4869, extracellular endogenous miR-16 and miR-146a
were reduced in a dose-dependent manner, while their cel-
lular expression levels remained unchanged. Furthermore,
miRNAs packaged in exosomes can be delivered to recipi-
ent cells where they exert gene silencing through the same
mechanism as cellular miRNAs [34]. Another study by
Pigati suggests that miRNAs release into blood, milk
and ductal fluids is selective and that this selectivity
may correlate with malignancy. In particular, while the
bulk of miR-451 and miR-1246 produced by malignant
mammary epithelial cells were released, the majority of
these miRNAs produced by non-malignant mammary
epithelial cells was retained [35]. It therefore seems
likely that the profiling of secretory miRNAs could be a
valuable cancer diagnostic and prognostic tool. How-
ever, intercellular trafficking mechanism that deter-
mines whether miRNAs are secreted or retained in
their originating cells requires further investigation [36].
While secretory miRNAs have been hypothesized to be
involved in mediating cell-cell communication, it remains
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with exosomes. Different opinions exist regarding this
issue. Using a mammalian cell culture model, Wang
et al. [37] showed that a significant fraction of extra-
cellular miRNAs resided outside of vesicles and acted
in exosome-independent manner. A number of RNA-
binding proteins, most importantly nucleophosmin 1
(NPM1), which were released into the cell culture
medium together with miRNAs may play a role in
protecting miRNAs from degradation. Another study by
Turchinovich et al. [38] found that most miRNAs in
plasma and cell culture media completely passed through
0.22 μm filters but remained in the supernatant after ultra-
centrifugation at 110000× g, indicating a non-vesicular
origin of extracellular miRNAs. In addition to revealing
that extracellular miRNAs were predominantly free of exo-
somes or microvesicles, they demonstrated an association
between miRNAs and the argonaute protein Ago2, an
RNA-induced silencing complex-related protein. They
hypothesized that circulating miRNAs were mostly by-
products of dead/dying cells that remain stably complexed
to Ago2 in the extracellular environment. However, some
miRNA/Ago2 complexes may be actively released from
cells and act in a paracrine manner. Furthermore, the
authors of this study do not reject the possibility that some
miRNAs may be associated with exosomes.
A third possibility exists. A large proportion of circulating
miRNAs are likely derived from blood cells and other
organs it is therefore possible that cancer-associated
miRNAs in the circulation may originate from immuno-
cytes in the tumor microenvironment or from some other
response mediated by the affected organ or system. Tumor
cells secrete a variety of miRNAs that act on immunocytes
to modulate immune responses and create either an immu-
nostimulatory or an immunotolerant tumor environment.
Conversely, immunocytes may secrete cancer-associated
miRNAs, thereby promoting or inhibiting proliferation, in-
vasion and apoptosis. As an example, there is an inverse
correlation between miR-17-92 expression and transform-
ing growth factor-β receptor II (TGFBR2) transcript levels
in CD 34+ hematopoietic stem cells [39]. Furthermore,
TGFBR2 is a verified target of miR-17-92 in solid cancers
[40]. It is therefore hypothesized that miR-17-92, expressed
in T cells, down-regulates TGFBR2 expression, thereby
making T cells more resistant to the immunosuppressive
effects of TGF-β, which is often expressed at high levels in
glioma [41]. Another miRNA, miR-21, was reported to con-
trol inflammation by regulating the pro-inflammatory
tumor suppressor programmed cell death 4 (PDCD4)
thereby promoting IL-10 production in macrophages [42].
On the other hand, miR-21 was found to promote
tumorigenesisi by downregulating phosphatase and tensin
homologue (PTEN) and activating v-akt murine thymoma
viral oncogene homolog (AKT) [43]. One of the firstmiRNAs linked with cancer, miR-155, upregulated by in-
flammatory stimuli in macrophages [44]. These links be-
tween alterations in miRNAs levels in inflammatory
reaction and tumorigenesis indicate that cancer-associated
miRNAs in the circulation may originate from the im-
munologic system, and that dysregulation of miRNAs may
be an important link between immunity and cancer.
Identifying the relationship between circulating miRNAs
and tissue miRNAs will be helpful in understanding the
origin of circulating miRNAs. Most studies to date found
the same trend of alteration between circulating miRNAs
and tissue miRNAs. For instance, Brase et al. found
that miR-375 and miR-141 were both highly expressed
in serum and tissue samples of prostate cancer patients
[45]. The levels of five miRNAs (miR-17-3p, miR-135b,
miR-222, miR-92 and miR-95) were also found to be
elevated in plasma and tissue samples of colorectal
cancer patients [46]. However, Wulfken et al. found
that 109 miRNAs were at higher levels in renal cell
carcinoma patients’ serum, but only 36 miRNAs were
upregulated in the corresponding tissue samples. It is
possible that only a subset of circulating miRNAs have
tumor-specific origins [47]. Another study reported
that about 66% but not all of the released miRNAs
reflects the cellular miRNAs abundance of malignant
mammary epithelial cells. These data suggest that cells
have a mechanism in place to select specific miRNAs
for cellular release or retention [35]. These studies
therefore demonstrate different sources of circulating
miRNAs, which makes it possible for circulating miRNAs
to reflect every aspect of the human physiological state.
Circulating miRNAs function
It is estimated that miRNAs regulate approximately 60%
of all protein-coding genes. Mature miRNAs regulate
gene expression by binding to complementary sites in
the target mRNA. The degree of complementarity between
miRNAs and their targets seems to determine the regulat-
ing results [48]. MiRNAs that bind to protein-coding
mRNA sequences with perfect complementarity could
induce the RNA-mediated interference (RNAi) pathway,
leading to cleavage of mRNA by Ago2 in the RNA-
induced silencing complex (RISC) [49]. However, im-
perfect base pairing between miRNA and the target
mRNA exists much more frequently in mammals. In this
case, miRNAs act by binding to sites within the 3′ untrans-
lated regions (3′UTRs) of their target protein-coding
mRNAs, leading to inhibition of expression of these genes
at the level of translation [50,51].
Recently, some studies have identified a number of
miRNAs that activate the expression of certain target genes
in a sequence-specific manner instead of silencing them [1].
Place et al. found that miR-373 induced expression of
E-cadherin and cold-shock domain-containing protein
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their promoters [52]. This novel mechanism is named
“RNA activation” (RNAa), a process that may require
the Ago2 protein and could be associated with histone
changes linked to gene activation [53]. The discovery of
RNAa introduces a new understanding of miRNA func-
tion which, in addition to an inhibitory effect, miRNAs
may also promote expression in certain instances.
Regarding their effect on cell biology, miRNAs can
have a profound effect on tumorigenesis. There is evi-
dence for a range of the modulatory effects of miRNAs
including cell proliferation, angiogenesis, apoptosis,
metastasis, invasion, and other biological processes.
For instance, miR-17-92 cluster can promote proliferation,
increase angiogenesis, and sustain cancer cell survival via
post-transcriptional repression of target mRNAs [54]. The
let-7 family, which were down-regulated in many malig-
nancies, inhibited cancer growth by targeting key regulators
of mitogenic pathways, such as RAS and high mobility
group A2 (HMGA2) [55]. miR-10b was highly expressed in
metastatic breast cancer cells and positively regulated cell
migration and invasion. Its overexpression in otherwise
non-metastatic breast tumors also initiated robust invasion
and metastasis [56]. miR-373 stimulated breast tumor cell
migration and invasion by suppressing CD44 gene expres-
sion [57]. As another example, miR-125b was found to in-
hibit apoptosis in neuroblastoma cells in a p53-dependent
manner [58]. Taken together, these studies indicate that
miRNAs have crucial effects in carcinogenesis and can ei-
ther act as oncogenes or tumor-suppressor genes.
Circulating miRNAs may have specific roles that are
dependent on their origin (Figure 1). Cancer cells may
evade the attacks of T and B cells by releasing immuno-
suppressive miRNAs. Cancer cells may also recruit
capillary blood vessels with angiogenic miRNAs. Alterna-
tively, surrounding cells may secrete tumor- suppressive
miRNAs, which block tumor growth and propagation.
Once the balance is disrupted, expansive growth of cancer
cells may follow [59-61]. Microvesicles derived from human
melanomas and colorectal carcinomas promote tumor
growth and immune escape by skewing monocyte differen-
tiation towards TGF β-secreting myeloid suppressive cells
[62]. On the other hand, miRNA-containing exosomes,
produced by dendritic cells and B lymphocytes, can deliver
the optimal signal for T cell activation. However, in some
instances they can also maintain peripheral tolerance by
inducing anergy in specific T cells or activation-induced cell
death, depending on the functional status of the originating
cells. MiRNAs released from tumor cells and immunocytes
may therefore work together resulting in poor clinical
outcomes [63-65].
MiRNAs are important modulators of tumor-associated
angiogenesis. The miR-17-92 cluster, which includes
miR-17, miR-18a, miR-19a/b, miR-20a, and miR-92a,has been linked to tumor angiogenesis. Overexpression
of the entire miR-17-92 cluster in myc-induced tumors
has been found to increase angiogenesis by paracrine
signaling [66]. However, overexpression of the individual
members of the miR-17-92 cluster reduced endothelial cell
sprouting, while inhibitors of these miRNAs augmented
angiogenesis in vitro, indicating that the miR-17-92 cluster
provides a cell-intrinsic antiangiogenic activity in endothe-
lial cells [67]. Another study by Grange et al. [68] found
that microvesicles released from CD105+ renal cancer
stem cells, in which 57 miRNAs were differentially
expressed, contributed to triggering the angiogenic switch
and coordinating metastatic diffusion during tumor pro-
gression. While miR-27b and let-7f were described as
proangiogenic miRNAs, miR-221 and miR-222 were identi-
fied as antiangiogenic miRNAs in endothelial cells [69-71].
MiRNAs may also influence angiogenesis by acting on
endothelial progenitor cells (EPCs) since EPCs play an im-
portant role in neovascularization. miR-34a was reported
as a tumor suppressor and regulates cell cycle, senescence,
apoptosis, and metabolism [72,73]. A recent study found
that overexpression of miR-34a in EPCs impaired EPC-
mediated angiogenesis by inducing senescence via the in-
hibition of silent information regulator 1 (SIRT 1). This
study provided a mechanistic insight on miRNA-mediated
regulation of EPC function [74]. The question of whether
in the course of EPC homing to tumor cells, circulating
miRNAs have some specific function remains unanswered.
They could conceivably act as chemokines, which direct
EPCs to tumor neovessels and promote vessel growth [75].
This topic certainly warrants further investigation.
Application of circulating miRNAs
Their stability and predictive property make miRNAs
ideal serum and plasma biomarkers in cancer patients. A
variety of independent studies have successfully proved
the importance of miRNAs as a tool of cancer diagnosis.
Wu and colleagues found that miR-21and miR-29 were
significantly upregulated in the serum of breast cancer
patients and may be useful biomarkers for breast cancer
detection [76,77]. In non-small cell lung cancer
(NSCLC), the expressions of miR-1254 and miR-574-5p
were significantly increased with respect to controls.
They were able to discriminate tumor samples from con-
trols with 82% and 77% sensitivity and specificity, respect-
ively, as judged by the use of a receiver operating
characteristic (ROC) curve [78]. Wei et al. also reported
that plasma levels of miR-21 were significantly higher in
NSCLC patients compared with their age- and sex-matched
controls, and that miR-21 can serve as a circulating tumor
biomarker for the early diagnosis of NSCLC [79]. Other
studies provide further support for the use of circulat-
ing miRNAs as non-invasive biomarkers for a wide
range of cancers, including hepatocellular carcinoma
Figure 1 Functional pattern of circulating miRNAs in cancer cells. Circulating miRNAs released by tumor cells may involve in angiogenesis,
distant immunoregulation and vascular mimicry of tumor cells. Periphery immunocytes may secrete tumor-suppressive miRNAs to block tumor
growth and propagation.
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[83] (Table 1). Moreover, researchers found that circu-
lating miRNAs might be used to detect early stage can-
cer. Zheng et al. reported that the levels of miR-155,
miR-197 and miR-182 in the plasma of lung cancer
patients, including stage I cancers, were significantly
elevated compared with controls. The combination of
these three miRNAs yielded 81.33% sensitivity and
86.76% specificity in discriminating lung cancer patients
from controls [84]. Schrauder and colleagues performed
microarray-based miRNA profiling on whole blood from
48 breast cancer patients at diagnosis along with 57 healthy
individuals as controls. All breast cancers were histologi-
cally confirmed as early stage invasive ductal carcinoma of
the breast with a tumor size ranging between 0.15 and
4.0 cm. They found that 59 miRNAs were significantly dif-able 1 Circulating miRNAs as diagnostic markers for different human cancers
isease miRNA Expression level Contributors
reast cancer miR-29a Up-regulation Wu et al., J Biomed Biotechnol. (2010) [76]
miR-21 Asaga et al., Clin Chem. (2011) [77]
ung cancer miR-21,1254,574-5p Up-regulation Wei et al., Chin J Cancer. (2011) [79]
Foss et al., J Thorac Oncol. (2011) [78]
epatocellular carcinoma miR-16,miR-199a Down-regulation Qu et al., J Clin Gastroenterol. (2011) [80]
miR-21,miR-122,miR-223 Up-regulation Xu et al., Mol Carcinog. (2010) [81]





MGastric cancer miR-1,20a,27a,34,423-5p Uferentially expressed in whole blood from cancer patients
compared with healthy controls, and that 13 and 46 miR-
NAs were significantly up- or down-regulated, respectively
[85]. Bianchi et al. developed a test, based on the detection
of 34 miRNAs from serum, that could identify early stage
NSCLC in a population of asymptomatic high-risk indivi-
duals with 80% accuracy [86].
In addition, some miRNAs may be useful prognostic
biomarkers for different cancers. Hu et al. [87] used
Solexa sequencing followed by qRT-PCR to test the
difference in serum levels of miRNAs between NSCLC
patients with longer and shorter survival. Eleven serum
miRNAs were found to be altered more than five-fold
between the two groups. Levels of four miRNAs (miR-486,
miR-30d, miR-1 and miR-499) were significantly asso-
ciated with overall survival, and this four-miRNA signaturep-regulation Liu et al., Eur J Cancer. (2011) [83]
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patients. Cheng et al. [88] found that plasma miR-141 was
an independent prognostic factor for advanced colon can-
cer and that high plasma levels of miR-141 were associated
with poor prognosis. Another study identified miR-221 as
a significant prognostic factor for poor overall survival in
colorectal cancer patients [89]. Additionally, researchers
reported the usefulness of circulating miRNAs in
evaluating treatment-response in cancer patients. For
instance, serum levels of miR-21 levels were elevated
in hormone-refractory prostate cancer patients, espe-
cially in those resistant to docetaxel-based chemother-
apy, making miR-21 a potential predictor for the
efficacy of docetaxel-based chemotherapy [90]. These
findings demonstrate that circulating miRNAs may be
useful in predicting patterns of sensitivity and resist-
ance to anti-cancer drugs.
Since the application of circulating miRNAs to the
field of cancer diagnostic is still new, certain points re-
main to be explored and normalized. One important
issue that needs to be addressed is the suitability of
different sample types for miRNA detection. While
Mitchell et al. found no significant differences when
comparing serum and plasma levels of miRNAs
[30,91], this result was limited to only four miRNAs
and might not reflect the global situation. Recently,
researchers found that serum samples yielded lower
miRNA concentrations [92]. Further study indicated
that the higher concentrations of miRNAs in plasma
compared with serum were mainly due to the presence
of cellular contaminants, and in particular, platelets.
To minimize the variation introduced by variable levels
of platelet contamination, serum samples should be
more suitable. Meanwhile, centrifugation protocols used
to separate serum or plasma require normalization before
results can be compared [93].
Another crucial issue is the use of appropriate
normalization controls. So far, several normalization strat-
egies have been used for the analysis of circulating miRNAs.
There is however no consensus. Some genes such as
RNU6B, 18S rRNA or 5S rRNA have been used to
normalize data [94,95], but other researchers considered
them highly variable or sensitive to degradation [96].
miR-16 has been used in many studies as an internal
normalization control [97,98], but was later found to be sus-
ceptible to hemolysis and was related to some diseases that
would make it unstable in circulation [80,93,99]. Synthetic
C. elegans miRNAs, such as Cel-miR-39 and Cel-miR-54
have been used as spike-in controls during RNA isolation
[100,101]. However, they were later found to be degraded
by RNase in the circulation. For the above reasons, some
researchers chose to perform normalization without the use
of a reference gene. For instance, Hu et al. [87] used ahealthy donor sample, which was processed together with
the test samples, to control for technical variability. Since
the coefficient of variation (CV) of Ct values for the control
sample between different plates for different miRNAs was
small, test reactions were comparable between different
plates. In addition, both the volume of serum and eluent
extracted for qRT-PCR were consistent throughout the
study. This strategy may minimize the variances among
samples and make the results more comparable [93]. Other
issues that need to be addressed include poor correlation
between different measurement platforms, lack of standar-
dized protocols for sample preparation and a suitable
method for measuring the concentration of miRNA in the
circulation.Conclusions
The discovery of circulating miRNAs brought forward a
new understanding of the basic mechanisms of oncogenesis
and opened up exciting prospects for diagnostics and prog-
nostics. Although still a new field, with much to be
explored, the hope is to apply circulating miRNAs to cancer
diagnosis and treatment, once we know more about their
origin and function. However, before novel biomarkers can
be routinely used in a clinical setting, standardized proce-
dures for sample preparation as well as a proper method for
normalization during analysis is essential. Large scale and
independent clinical studies will also be required.
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